Compare · CSTL vs HUM
CSTL vs HUM
Side-by-side comparison of Castle Biosciences Inc. (CSTL) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CSTL and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $45.53B, about 72.5x CSTL ($627.8M).
- Over the past year, CSTL is up 7.3% and HUM is up 61.0% - HUM leads by 53.7 points.
- CSTL has been more active in the news (18 items in the past 4 weeks vs 3 for HUM).
- HUM has more recent analyst coverage (25 ratings vs 5 for CSTL).
- Company
- Castle Biosciences Inc.
- Humana Inc.
- Price
- $20.68-1.43%
- $379.28+2.84%
- Market cap
- $627.8M
- $45.53B
- 1M return
- +14.13%
- +24.47%
- 1Y return
- +7.32%
- +60.97%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 18
- 3
- Recent ratings
- 5
- 25
Castle Biosciences Inc.
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest CSTL
- Pres. & Chief Exec. Officer Maetzold Derek J exercised 6,214 shares at a strike of $2.39 and sold $205,149 worth of shares (9,836 units at $20.86) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Castle Biosciences Inc.
- SEC Form 4 filed by Director Olson Tiffany
- SEC Form 4 filed by Director Goldberg Ellen
- SEC Form 4 filed by Director Harrison Miles
- SEC Form 4 filed by Director Cotton Rodney
- SEC Form 4 filed by Director Caple Kim
- SEC Form 4 filed by Director Bradbury Daniel
- SEC Form 4 filed by Director Cole G Bradley
- Castle Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest HUM
- Humana Announces Agreement to Divest Minority Interest in Gentiva
- Humana Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Humana completes $83 million Florida infrastructure investment to deepen coordinated patient care approach
- Humana upgraded by Deutsche Bank with a new price target
- Humana Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Humana, CenterWell and USAA Unite with VFW for National Day of Service Supporting Veterans Experiencing Homelessness
- Humana Invests More Than $1 Million to Advance Health Outcomes Across Louisiana
- Chief Financial Officer Mellet Celeste gave a grant of 15,387 units of Humana Common, decreasing direct ownership by 28% to 39,637 units (SEC Form 4)
- Chief Information Officer Mehta Japan was granted 9,448 units of Humana Common, increasing direct ownership by 122% to 17,176 units (SEC Form 4)
- President, Enterprise Growth Dintenfass David was granted 11,273 units of Humana Common, increasing direct ownership by 80% to 25,407 units (SEC Form 4)